You are here: Industry Insights > Stargardt Disease

News List

reVision Therapeutics Announces FDA Grant, Orphan-Drug Designation for Stargardt Disease Treatment americanpharmaceuticalreview
November 06, 2020
reVision Therapeutics announced the US Food and Drug Administration (FDA) has granted the Company's request to designate REV-0100 as an Orphan-Drug and a Rare Pediatric Disease Drug for the treatment of Stargardt disease.
Belite Bio Announces Positive Results from LBS-008 Trial for Dry AMD, Stargardt Disease americanpharmaceuticalreview
July 27, 2020
Belite Bio announced positive results from two Phase 1 clinical trials in the United States and Australia for LBS-008, a First-in-Class oral small molecule Retinol Binding Protein 4 (RBP4) specific antagonist aimed to treat atrophic Age-related ...
Acucela gets EMA approval for Emixustat to treat Stargardt disease biospectrumasia
June 13, 2019
Upon receiving the orphan designation, the sponsor will qualify for multiple development incentives
FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 americanpharmaceuticalreview
September 18, 2018
Lin BioScience announced the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to LBS-008...